CD226 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, in our study, three of the four surveyed activating receptors (NKG2D, NKp30, and DNAM-1) rebounded in surface expression after successful TKI treatments for CML (Figure S4), and the number of cytotoxic NK cells expressing these activating receptors also reverted or increased simultaneously.